Nautilus Biotechnology (NAUT) Change in Accured Expenses (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Change in Accured Expenses of $248000.0 for Q2 2026, up 93.75% sequentially from $128000.0 in Q1 2026, and up 283.7% YoY from $64633.2 in Q2 2025.
Nautilus Biotechnology (NAUT) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Change in Accured Expenses for 7 years, with the latest figure at $248000.0 in Q2 2026.
- Quarterly Change in Accured Expenses rose 283.7% year-over-year to $248000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $615000.0 (up 304.32% YoY) and the FY2025 annual result came in at $629000.0, up 145.03% from the prior year.
- Change in Accured Expenses rose to $248000.0 in Q2 2026 per NAUT's latest filing, from $128000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $942000.0 in Q3 2025 and troughed at -$703000.0 in Q4 2025.
- A 5-year average of $24111.1 and a median of -$79000.0 in 2024 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses tumbled 512.31% in 2024, then jumped 4195.65% in 2025.
- Over 5 years, Change in Accured Expenses stood at -$451000.0 in 2022, then grew by 24.61% to -$340000.0 in 2023, then plunged by 96.47% to -$668000.0 in 2024, then declined by 5.24% to -$703000.0 in 2025, then surged by 135.28% to $248000.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $248000.0, $128000.0, and -$703000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Nautilus Biotechnology | 120.16 Mn | 120.16 Mn | 175,000.00 | 248,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 248,000.00 |
| Jun 30, 2026 | 248,000.00 |
| Mar 31, 2026 | 128,000.00 |
| Mar 31, 2026 | 128,000.00 |
| Dec 31, 2025 | -703,000.00 |
| Dec 31, 2025 | -703,000.00 |
| Sep 30, 2025 | 942,000.00 |
| Sep 30, 2025 | 942,000.00 |
| Jun 30, 2025 | -135,000.00 |
| Jun 30, 2025 | -135,000.00 |
| Mar 31, 2025 | 525,000.00 |
| Mar 31, 2025 | 525,000.00 |
| Dec 31, 2024 | -668,000.00 |
| Dec 31, 2024 | -668,000.00 |
| Sep 30, 2024 | -23,000.00 |
| Sep 30, 2024 | -23,000.00 |
| Jun 30, 2024 | -438,000.00 |
| Jun 30, 2024 | -438,000.00 |
| Mar 31, 2024 | -268,000.00 |
| Mar 31, 2024 | -268,000.00 |